AORT Artivion
Artivion earnings company data as of 4:45 AM ET 11/7
- 0 of 1 EPS beats
History
1 period, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | 0.11 | 0.08 | Miss -27.3% |
| Rev | $121.0M | $123.8M | Beat +2.3% |
Insider trades
Open-market buys and sales by AORT's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $7.2M sold by 7 insiders outside a trading plan
- $4.9M sold by 4 insiders under 10b5-1 plans
-
Andrew M Green SVP, Regulatory and QualitySale$287K 11,480 shares at $24.97 22% of stakeTraded Sep 10 Filed Sep 11
-
Andrew M Green SVP, Regulatory and QualitySale$216K 8,003 shares at $27.03 13% of stakeTraded Sep 2–3 Filed Sep 4
-
James P Mackin CEOSale$2M 70,000 shares at $28.96 7.4% of stakeTraded Aug 19 Filed Aug 20
-
Jean F Holloway SVP, General CounselSale$28K 977 shares at $28.49 0.5% of stakeTraded Aug 12 Filed Aug 12
-
Andrew M Green SVP, Regulatory and QualityPlanned sale$911K 44,001 shares at $20.70 42% of stakeTraded Jun 11 Filed Jun 15
-
Jean F Holloway SVP, General CounselSale$341K 8,962 shares at $38.00 4.6% of stakeTraded Mar 4 Filed Mar 4
-
John E Davis Chief Commercial OfficerSale$226K 5,000 shares at $45.11 2.5% of stakeTraded Dec 15, 2025 Filed Dec 17, 2025
-
James P Mackin CEOPlanned sale$1.4M 30,921 shares at $45.46 3.7% of stakeTraded Dec 3, 2025 Filed Dec 4, 2025
-
Jean F Holloway SVP, General CounselSale$331K 7,315 shares at $45.30 4.5% of stakeTraded Dec 3, 2025 Filed Dec 4, 2025
-
James P Mackin CEOPlanned sale$1.4M 30,921 shares at $45.56 3.7% of stakeTraded Dec 2, 2025 Filed Dec 3, 2025
-
Marshall S. Stanton SVP, Clinical & MD AffairSale$2.1M 47,376 shares at $45.04 51% of stakeTraded Nov 21, 2025 Filed Nov 24, 2025
-
Marshall S. Stanton SVP, Clinical & MD AffairSale$675K 15,276 shares at $44.18 25% of stakeTraded Nov 20, 2025 Filed Nov 24, 2025
-
Elizabeth A Hoff DirectorSale$189K 4,200 shares at $45.10 13% of stakeTraded Nov 18, 2025 Filed Nov 19, 2025
-
Jean F Holloway SVP, General CounselPlanned sale$577K 12,787 shares at $45.09 7.3% of stakeTraded Nov 14–17 Filed Nov 18, 2025
-
John E Davis Chief Commercial OfficerPlanned sale$574K 12,787 shares at $44.92 6% of stakeTraded Nov 14–17 Filed Nov 18, 2025
Also filed in the last 12 months, not counted as buying or selling: 37 sales to cover taxes, 20 stock grants, 13 option exercises, 2 other transactions, and 1 gift.
SEC filings
Recent issuer filings from EDGAR, 14 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 1.01,2.02,9.01 | Filing Doc | |
| DEF 14A | DEFINITIVE PROXY STATEMENT | Filing Doc | |
| DEFA14A | ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon
- Financial Intelligence, Revised Ed. View on Amazon